Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

Autor: Christina Demuth, Karen-Lise Garm Spindler, Julia S. Johansen, Niels Pallisgaard, Dorte Nielsen, Estrid Hogdall, Benny Vittrup, Boe Sandahl Sorensen

Publikováno v: Translational Oncology, Vol 11, Iss 5, Pp 1220-1224 (2018)

Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as new tools in aiding the treatment of cancer patients. Studies show that total cfDNA bears prognostic value in metastatic colorectal cancer (mCRC) and that meas

Externí odkaz: https://doaj.org/article/ca369baa4b6543468aa1c0f5950e09fe

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

Autor: Diaz, Luis A, Jr ^*, Shiu, Kai-Keen, Kim, Tae-Won, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis, Smith, Denis, Garcia-Carbonero, Rocio, Benavides, Manuel, Gibbs, Peter, de la Fourchardiere, Christelle, Rivera, Fernando, Elez, Elena, Le, Dung T, Yoshino, Takayuki, Zhong, Wen Yan, Fogelman, David, Marinello, Patricia, Andre, Thierry

Publikováno v: In The Lancet Oncology May 2022 23(5):659-670

Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

Autor: Yoshino, Takayuki, Andre, Thierry, Kim, Tae Won, Yong, Wei Peng, Shiu, Kai-Keen, Jensen, Benny Vittrup, Jensen, Lars Henrik, Punt, Cornelis J. A., Smith, Denis, García-Carbonero, Rocío, Alcaide-Garcia, Julia, Gibbs, Peter, de la Fouchardiere, Christelle, Rivera, Fernando, Elez, Elena, Le, Dung T., Adachi, Noriaki, Fogelman, David, Marinello, Patricia, Diaz, Luis A., Universitat Autònoma de Barcelona

Publikováno v: Cancer Science 2022; 00: 1-11
Scientia

The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::214c1d92151f8f2cf9363aefde0e09a2
https://pubmed.ncbi.nlm.nih.gov/36369901

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177):final analysis of a randomised, open-label, phase 3 study

Autor: Luis A Diaz, Kai-Keen Shiu, Tae-Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardiere, Fernando Rivera, Elena Elez, Dung T Le, Takayuki Yoshino, Wen Yan Zhong, David Fogelman, Patricia Marinello, Thierry Andre

Publikováno v: KEYNOTE-177 Investigators 2022, ' Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177) : final analysis of a randomised, open-label, phase 3 study ', The Lancet Oncology, vol. 23, no. 5, pp. 659-670 . https://doi.org/10.1016/S1470-2045(22)00197-8
Lancet Oncol
The Lancet Oncology, 23(5), 659-670. Lancet Publishing Group

Background: Pembrolizumab has shown improved progression-free survival versus chemotherapy in patients with newly diagnosed microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. However, the treatment's effect on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02a04667b6513528277e21702f548f74
https://portal.findresearcher.sdu.dk/da/publications/141a15cb-1769-437d-8d1c-e6c02310d91d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.